The heterogeneity of the studies limited the analysis , but together they showed that provision of risk information to patients improved the accuracy of risk perception without decreasing quality of life or increasing anxiety , but had little effect on lifestyle .
There seems evidence that providing CVD risk model estimates to professionals and patients improves perceived CVD risk and medical prescribing , with little evidence of harm on psychological well-being
OBJECTIVE To systematic ally review whether the provision of information on cardiovascular disease ( CVD ) risk to healthcare professionals and patients impacts their decision-making , behaviour and ultimately patient health .
Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary Prevention: Balancing Longevity Benefits Against Medication Disutility
Background — Primary prevention guidelines focus on risk , often assuming negligible aversion to medication , yet most patients discontinue primary prevention statins within 3 years . We quantify real-world distribution of medication disutility and separately calculate the average utilities for a range of risk strata . Method and Results — We r and omly sample d 360 members of the general public in London . Medication aversion was quantified as the gain in lifespan required by each individual to offset the inconvenience ( disutility ) of taking an idealized daily preventative tablet . In parallel , we constructed tables of expected gain in lifespan ( utility ) from initiating statin therapy for each age group , sex , and cardiovascular risk profile in the population . This allowed comparison of the widths of the distributions of medication disutility and of group-average expectation of longevity gain . Observed medication disutility ranged from 1 day to > 10 years of life being required by subjects ( median , 6 months ; interquartile range , 1–36 months ) to make daily preventative therapy worthwhile . Average expected longevity benefit  from statins at ages ≥50 years ranges from 3.6 months ( low-risk women ) to 24.3 months ( high-risk men ) . Conclusion — We can no longer assume that medication disutility is almost zero . Over one-quarter of subjects had disutility exceeding the group-average longevity gain  from statins expected even for the highest-risk ( ie , highest-gain ) group . Future primary prevention studies might explore medication disutility in larger population s. Patients may differ more in disutility than in prospect ively definable utility ( which provides only group-average estimates ) . Consultations could be enriched by assessing disutility and exploring its reasons
The heterogeneity of the studies limited the analysis , but together they showed that provision of risk information to patients improved the accuracy of risk perception without decreasing quality of life or increasing anxiety , but had little effect on lifestyle .
There seems evidence that providing CVD risk model estimates to professionals and patients improves perceived CVD risk and medical prescribing , with little evidence of harm on psychological well-being
OBJECTIVE To systematic ally review whether the provision of information on cardiovascular disease ( CVD ) risk to healthcare professionals and patients impacts their decision-making , behaviour and ultimately patient health .